In all critical stages in the drug life cycle, BaiPharm can provide specific recommendations and actionable solutions to clients.
WEBINARS MORE >
China Market Entry & Branding for OTC Products
[ Tuesday ,20th December 2022 ]
How to Submit New Drug Application (NDA) in China
[ Tuesday ,6th December 2022 ]
OTC Drug Focus: How to Start and Manage Your Cross-border E-commerce (CBEC) Operations in China
[ Thursday ,3rd November 2022 ]
OTC Drug Focus: China Market Overview and CBEC Channel Analysis
[ Wednesday ,26th October 2022 ]
Marketing Approval Priority Review and Approval Innovative Drug Generic Drug Biological Product Cancer Drug Registration New Drug COVID-19Monthly Report: New Drug Approvals in China | January 2023 In January 2023, China NMPA approved 15 new drugs, including 8 chemical drugs and 7 biological products. Simcere's Simnotrelvir Tablets / Ritonavir Tablets and Shanghai Vinnerna Biosciences' Deuremidevir Hydrobromide got conditional approvals for COVID-19 treatment.
Feb 03, 2023
China Adds 111 Drugs to 2022 National Reimbursement Drug List On Jan. 18, 2023, China issued the 2022 National Reimbursement Drug List (NRDL), a list of drugs fully or partially reimbursed by the national basic health insurance. After bidding or price negotiation between NHSA and pharma companies, 111 drugs entered the 2022 NRDL and 3 drugs were delisted. The average price cut reached 60.1%.
Jan 20, 2023
Law & Regulation Pharmacovigilance Marketing Approval Volume-Based Procurement Generic Drug Drug Registration E-commerce2022 Recap: Top 10 BaiPharm Stories on China Pharmaceutical Regulations ChemLinked BaiPharm Portal has been tracking and interpreting China’s pharmaceutical regulations during the year of 2022. Here are the top 10 stories we selected for you to grasp China’s regulatory dynamics.
Jan 13, 2023
Monthly Recap: China Pharmaceutical Regulatory Updates | December 2022 Check out China's pharmaceutical regulatory updates in December 2022: 1. China NMPA Adds OTC Status to a Former Prescription Drug; 2. China NMPA Releases the 62nd List of RLDs; 3. China NMPA Issues Regulation on Supervising MAH as the Main Responsible Entity for Drug Safety; 4. China NMPA Requires Licenses for Importing and Exporting Anesthetics and Psychoactive Drugs; 5. China CDE Specifies Requirements for Electronic Submission of Drug Applications...
Jan 09, 2023
China Conditionally Approves MSD's Molnupiravir for COVID-19 Treatment On Dec. 29, 2022, China NMPA conditionally approved Merck Sharp & Dohme (MSD)’s Molnupiravir Capsules (brand name: Lagevrio) for COVID-19 treatment.
Jan 05, 2023
China Levies Zero Tariff on Active Pharmaceutical Ingredients of COVID-19, Cancer, and Rare Disease Drugs According to China's 2023 Tariff Adjustment Plan, tariffs are provisionally lowered to zero for 22 categories of active pharmaceutical ingredients of medicines for treating COVID-19, cancer, and rare diseases.
Jan 05, 2023